Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | LCK | P06239 | 3/20 | 0.45 |
| ▸ | FYN | P06241 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | LYN | P07948 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | FRK | P42685 | 3/20 | 0.45 |
| ▸ | CLK2 | P49760 | 3/20 | 0.45 |
| ▸ | BLK | P51451 | 3/20 | 0.45 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.45 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.45 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.45 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.45 |
| ▸ | FES | P07332 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357758 | 0.89 | BRAF (0.48) | BRAFCYP2C19CYP2C9MAP4K4ABL1 | |
| SCHEMBL3505554 | 0.85 | BRAF (0.57) | BRAFCYP2C19CYP2C9PTK6MAP4K5 | |
| SCHEMBL3505940 | 0.84 | CYP2C19 (0.52) | BRAFCYP2C19CYP2C9MAP4K4ABL1 | |
| SCHEMBL13505690 | 0.84 | BRAF (0.52) | BRAFCYP2C19CYP2C9MAP4K4ABL1 | |
| SCHEMBL298199 | 0.83 | BRAF (0.62) | BRAFCYP2C19CYP2C9MAP4K4ABL1 | |
| SCHEMBL30078249 | 0.83 | BRAF (0.62) | BRAFCYP2C19CYP2C9MAP4K4ABL1 | |
| SCHEMBL3703309 | 0.83 | BRAF (0.51) | BRAFCYP2C19CYP2C9MAP4K4ABL1 | |
| SCHEMBL2015374 | 0.82 | BRAF (0.66) | BRAFCYP2C19CYP2C9MAP4K4ABL1 | |
| SCHEMBL297941 | 0.82 | BRAF (0.50) | BRAFCYP2C19CYP2C9MAP4K4ABL1 | |
| SCHEMBL293715 | 0.82 | BRAF (0.64) | BRAFCYP2C19CYP2C9MAP4K4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | claimed |
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | claimed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| EP-2395004-B1 | Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors | PLEXXIKON INC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8415469-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | BRAF 95/4885CYP2C19 4868/4885CYP2C9 4869/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | BRAF 1/4885CYP2C19 2730/4885CYP2C9 2176/4885 |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885CYP2C19 4579/4885CYP2C9 4746/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885CYP2C19 4579/4885CYP2C9 4746/4885 |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885CYP2C19 4579/4885CYP2C9 4746/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885CYP2C19 4579/4885CYP2C9 4746/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885CYP2C19 4579/4885CYP2C9 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.